Design of tetrapeptide ligands as inhibitors of the Src SH2 domain
Date of Original Version
Src homology-2 (SH2) domains are noncatalytic motifs containing approximately 100 amino acid residues that are involved in intracellular signal transduction. The phosphotyrosine-containing tetrapeptide pTyr-Glu-Glu-Ile (pYEEI) binds to Src SH2 domain with high affinity (Kd=100 nM). The development of five classes of tetrapeptides as inhibitors for the Src SH2 domain is described. Peptides were prepared via solid-phase peptide synthesis and tested for affinity to Src SH2 domain using a fluorescence polarization based assay. All of the N-terminal substituted pYEEI derivatives (class II) presented binding affinity (IC50=of 2.7-8.6 μM) comparable to pYEEI (IC50=6.5 μM) in this assay. C-Terminal substituted pYEEI derivatives (class III) showed a lower binding affinity with IC50 values of 34-41 μM. Amino-substituted phenylalanine derivatives (class IV) showed weak binding affinities (IC50=16-153 μM). Other substitutions on phenyl ring (class I) or the replacement of the phenyl ring with other cyclic groups (class V) dramatically decreased the binding of tetrapeptides to Src SH2 (IC50>100 μM). The ability of pYEEI and several of the tetrapeptides to inhibit the growth of cancer cells were assessed in a cell-based proliferation assay in human embryonic kidney (HEK) 293 tumor cells. The binding affinity of several of tested compounds against Src SH2 domain correlates with antiproliferative activity in 293T cells. None of the compounds showed any significant antifungal activity against Candida albicans ATCC 14053 at the maximum tested concentration of 10 μM. Overall, these results provided the structure-activity relationships for some FEEI and YEEI derivatives designed as Src SH2 domain inhibitors. © 2003 Elsevier Ltd. All rights reserved.
Publication Title, e.g., Journal
Bioorganic and Medicinal Chemistry
Nam, Nguyen Hai, Rebecca L. Pitts, Gongqin Sun, Soroush Sardari, Amie Tiemo, Mingxing Xie, Bingfang Yan, and Keykavous Parang. "Design of tetrapeptide ligands as inhibitors of the Src SH2 domain." Bioorganic and Medicinal Chemistry 12, 4 (2004). doi: 10.1016/j.bmc.2003.10.060.